Jan Baughman

Learn More
Background Margetuximab is an anti-HER2 antibody that binds with elevated affinity to both the lower and higher affinity forms of CD16A, an Fc-receptor important for antibody dependent cell-mediated cytotoxicity (ADCC) against tumor cells. A Phase 1 study was initiated to evaluate the toxicity profile, maximum tolerated dose (MTD), pharmacokinetics, and(More)
AML is characterized by excessive proliferation and infiltration of neoplastic cells of hematopoietic origin. AML occurs at a median age of 67 and will lead to an estimated 10,460 deaths in the United States in 2014. Therapy for AML has changed little in the last 30 years, and consists of an induction regimen of cytotoxic chemotherapy, followed by(More)
Background MGA271 is an Fc optimized humanized IgG1 monoclonal antibody that binds to B7-H3 (CD276), a member of the B7 family, currently undergoing Phase I testing. The Fc domain is engineered for enhanced binding to the activating FcgR, CD16A, and decreased binding to the inhibitory FcgR, CD32B. B7-H3 has limited expression in normal tissue and high(More)
Background MGA271 is an Fc optimized, humanized IgG1 monoclonal antibody targeting B7-H3 (CD276), a member of the B7 family, and is currently undergoing Phase I testing. The Fc domain is engineered for enhanced binding to the activating FcgR, CD16A, and decreased binding to the inhibitory FcgR, CD32B. B7-H3 exhibits limited expression on normal tissues, but(More)
In order to study the effect of daily (circadian) rhythm on toxicity of an anticancer drug, 5-fluorouracil, adult female C3H mice were used in this work. A dose of 200 mg/kg of 5-FU was administered intraperitoneally to the animals. Body weights and animal mortality were observed daily during the following 21 days after administration of the drug. The most(More)
OBJECTIVE Systemic sclerosis (SSc) is a disorder characterized by progressive thickening of the skin; there is no effective therapy. PVAC, a potential therapeutic agent derived from delipidated, deglycolipidated Mycobacterium vaccae, has shown effects on cutaneous disease in animal models of SSc. We evaluated the safety and possible biologic effect of(More)
OBJECTIVE Human cartilage glycoprotein 39 (HC gp-39) appears to be a relevant autoantigen in patients with rheumatoid arthritis (RA). Administration of major histocompatibility complex (MHC) Class II complexed antigens without requisite costimulatory signals can induce immunologic tolerance. We evaluated the safety, pharmacokinetics, and preliminary(More)
PURPOSE RAV12 is a high affinity, internalizing, chimeric IgG1 monoclonal antibody that binds RAAG12, a novel primate-restricted N-linked carbohydrate epitope present on multiple cell surface proteins. RAAG12 is highly expressed on many adenocarcinomas, particularly those of gastrointestinal origin. A phase 1 dose-escalation safety and pharmacokinetics(More)
  • 1